* Regulus Therapeutics Inc RGLS.OQ reported a quarterly
adjusted
loss of 17 cents per share for the quarter ended in June,
higher than the same quarter last year, when the company
reported EPS of -37 cents. The mean expectation of six analysts
for the quarter was for a loss of 15 cents per share. Wall
Street expected results to range from -26 cents to -12 cents per
share.
* Reported revenue was zero; analysts expected zero.
* Regulus Therapeutics Inc's reported EPS for the quarter
was a
loss of 17 cents.
* The company reported a quarterly loss of $11.04 million.
* Regulus Therapeutics Inc shares had fallen by 18.2% this
quarter and gained 14.1% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by
about 27.5%
in the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"
Wall Street's median 12-month price target for Regulus
Therapeutics Inc is $7.50
This summary was machine generated from LSEG data August 8 at
10:30 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Jun. 30 2024 -0.15 -0.17 Missed
Mar. 31 2024 -0.22 -0.29 Missed
Dec. 31 2023 -0.39 -0.40 Missed
Sep. 30 2023 -0.40 -0.40 Met